Sign Out
Pregnancy: There are no adequate data from the use of Teneligliptin plus Pioglitazone combination tablet in pregnant women. Studies in animals have shown reproductive toxicity at high doses of DPP-4 inhibitors.
Teneligliptin plus Pioglitazone tablet should not be used during pregnancy. If a patient wishes to become pregnant or if a pregnancy occurs, treatment should be discontinued and switched to insulin treatment as soon as possible.
Lactation: In studies performed with the individual active substances, DPP-4 inhibitors and Pioglitazone are excreted in the milk of lactating rats. Teneligliptin plus Pioglitazone tablet must therefore not be used in women who are breast-feeding.
Continue with Google